Get the Stockscreener App
3.35
3.40%
0.11
Agenus Inc stock is traded at $3.35, with a volume of 833.26K.
It is up +3.40% in the last 24 hours and up +9.12% over the past month.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
See More
Previous Close:
$3.24
Open:
$3.24
24h Volume:
833.26K
Relative Volume:
0.91
Market Cap:
$139.50M
Revenue:
$123.87M
Net Income/Loss:
$62.49M
P/E Ratio:
2.0066
EPS:
1.6695
Net Cash Flow:
$-87.53M
1W Performance:
-4.01%
1M Performance:
+9.12%
6M Performance:
-14.32%
1Y Performance:
-43.41%
1-Day Range:
$3.10
$3.385
1-Week Range:
$3.10
$3.63
52-Week Range:
$2.71
$7.34
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.35 | 139.50M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 - AOL.com
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - AOL.com
Form 4 Agenus Inc For: 7 July By Investing.com - Investing.com Nigeria
Agenus (NASDAQ: AGEN) director Harrison awarded 8,547 shares as board compensation - Stock Titan
Director Wright of Agenus (NASDAQ: AGEN) granted deferred stock units - Stock Titan
Agenus Inc. Amends Notes and Issues New Warrants in 2026 Definitive Agreement – Key Details and Terms - Minichart
Agenus Extends $5.09M Notes to 2027, Lengthens Warrants to 2031 and Issues New D Warrants - TradingView
Agenus (NASDAQ: AGEN) extends note maturity and long-dated warrants - Stock Titan
Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI - Oncodaily
Agenus BOT+BAL Shows 33% Three-Year Survival in Immunotherapy-Resistant Colorectal Cancer - BioPharm International
BOT+BAL Continues to Show Durable Clinical Benefit in MSS mCRC – Agenus - Oncodaily
Agenus (AGEN) Reports Promising Data on BOT/BAL Therapy for Colo - GuruFocus
Agenus reports 3-year survival data in colorectal cancer study - grafa.com
Agenus Achieves 33% Three-Year Survival in Colorectal Cancer - AllSci
Agenus reports 3-year survival data for colorectal cancer therapy - Investing.com
Agenus (AGEN) Reports Promising Long-Term Survival Data for BOT+ - GuruFocus
Agenus reports 3-year survival data for colorectal cancer therapy By Investing.com - Investing.com Nigeria
Form 4 Agenus Inc For: 30 June By Investing.com - Investing.com Australia
Agenus (AGEN) director Armen takes June 2026 salary in 5,364 company shares - Stock Titan
Agenus Inc.(NasdaqCM: AGEN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Index - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2500 Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Value Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Value Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Index - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Growth Benchmark - marketscreener.com
Durable Outcomes in MSS Metastatic Colorectal Cancer Without Active Liver MetastasesAgenus - Oncodaily
Price to sales forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Enterprise value to EBITDA forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Enterprise value to revenue forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Price to book forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Enterprise value to EBIT forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Agenus Inc. Actuals & Estimates (BX:AGEN) - TradingView
Agenus Inc. Actuals & Estimates (NASDAQ:AGEN) - TradingView
AGEN Forecast — Price Target — Prediction for 2027 - TradingView
Agenus Inc. Actuals & Estimates (TRADEGATE:AJ8) - TradingView
Agenus to present 3-year cancer trial data at ESMO conference - Investing.com South Africa
Agenus Challenges 'Untreatable' Status of a Common Colorectal Cancer - BriefGlance
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 - BioSpace
Agenus (AGEN) Set to Present Promising Survival Data at ESMO 202 - GuruFocus
Agenus Announces Three-Year Survival Data From Phase 1B Bot+Bal Study In Mss Metastatic Colorectal Cancer To Be Presented At Esmo Gi 2026 - TradingView
Agenus Shareholders Approve Governance, Compensation and Auditors - The Globe and Mail
Speed and Rigor Are Not in Conflict – Garo Armen - Oncodaily
Form 8K Agenus Inc For: 23 June By Investing.com - Investing.com Nigeria
Agenus Inc. Files Form 8-K with SEC: Corporate Details, Stock Information & Key Disclosures (June 16, 2026) 25 - Minichart
Form 8K Agenus Inc For: 23 June - Investing.com UK
Agenus (NASDAQ: AGEN) investors approve equity plan changes and KPMG - Stock Titan
Agenus Inc (AGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Agenus Inc (AGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agenus Inc (AGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):